BRPI0517976A - métodos de tratamento - Google Patents

métodos de tratamento

Info

Publication number
BRPI0517976A
BRPI0517976A BRPI0517976-9A BRPI0517976A BRPI0517976A BR PI0517976 A BRPI0517976 A BR PI0517976A BR PI0517976 A BRPI0517976 A BR PI0517976A BR PI0517976 A BRPI0517976 A BR PI0517976A
Authority
BR
Brazil
Prior art keywords
methods
treatment methods
patient
treatment
temozolomide
Prior art date
Application number
BRPI0517976-9A
Other languages
English (en)
Inventor
Chen Zong
Benjamin Winograd
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36168622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0517976A publication Critical patent/BRPI0517976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MéTODOS DE TRATAMENTO. Trata-se de métodos para tratar câncer em um paciente necessitado de tal tratamento que compreende administrar temozolomida de acordo com um regime e/ou programas de dosagem aperfeiçoados baseados no nível de MGMT do paciente. Métodos aperfeiçoados adicionais para tratar os pacientes com temozolomida também são descritos.
BRPI0517976-9A 2004-11-09 2005-11-07 métodos de tratamento BRPI0517976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62625804P 2004-11-09 2004-11-09
PCT/US2005/040449 WO2006052976A2 (en) 2004-11-09 2005-11-07 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level

Publications (1)

Publication Number Publication Date
BRPI0517976A true BRPI0517976A (pt) 2008-10-21

Family

ID=36168622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517976-9A BRPI0517976A (pt) 2004-11-09 2005-11-07 métodos de tratamento

Country Status (13)

Country Link
US (2) US20060100188A1 (pt)
EP (1) EP1830845A2 (pt)
JP (2) JP2008519584A (pt)
CN (1) CN101098696A (pt)
AU (1) AU2005304672B2 (pt)
BR (1) BRPI0517976A (pt)
CA (1) CA2585446A1 (pt)
MX (1) MX2007005581A (pt)
NO (1) NO20072931L (pt)
NZ (1) NZ554831A (pt)
TW (1) TW200630089A (pt)
WO (1) WO2006052976A2 (pt)
ZA (1) ZA200703716B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476494C (en) * 2002-02-22 2010-04-27 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
US20070265324A1 (en) * 2006-01-17 2007-11-15 Wolfgang Wernet Combination Therapy with Parp Inhibitors
PT2004646T (pt) 2006-04-05 2016-07-14 Opko Health Inc Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2007133496A2 (en) * 2006-05-09 2007-11-22 Schering Corporation Development of a novel assay for mgmt (methyl guanine transferase)
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
EP2409700A1 (en) * 2007-05-08 2012-01-25 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
CA2908353C (en) * 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN110408694A (zh) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法
MX2021011760A (es) * 2019-03-28 2021-12-10 Univ Jefferson Metodos para el tratamiento de canceres usando antisentido.
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5876146A (en) * 1995-10-27 1999-03-02 General Electric Company Apparatus and methods for repairing jet pump diffusers in a nuclear reactor
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
BR0009380A (pt) * 1999-03-30 2001-12-26 Schering Corp Tratamento de câncer melhorado comtemozolomida
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
WO2001085221A2 (en) * 2000-05-12 2001-11-15 Duke University Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
JP2004509643A (ja) * 2000-09-29 2004-04-02 ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン アルキル化剤を用いた化学療法による治療に対する臨床反応を予測する方法
WO2002103013A2 (en) * 2000-10-30 2002-12-27 Gene Logic, Inc. Partially double-stranded nucleic acids, methods of making, and use thereof
EP1344777B1 (en) * 2000-11-20 2011-03-16 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
US20060183168A1 (en) * 2002-10-28 2006-08-17 Geroni Maria C Method for optimizing therapeutic efficacy of nemorubicin
WO2004086949A2 (en) * 2003-03-25 2004-10-14 John Wayne Cancer Institute Dna markers for management of cancer
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule

Also Published As

Publication number Publication date
JP2011121960A (ja) 2011-06-23
US20060100188A1 (en) 2006-05-11
ZA200703716B (en) 2008-09-25
EP1830845A2 (en) 2007-09-12
MX2007005581A (es) 2007-05-23
AU2005304672A1 (en) 2006-05-18
AU2005304672B2 (en) 2010-03-11
NO20072931L (no) 2007-08-03
NZ554831A (en) 2009-10-30
US20090247598A1 (en) 2009-10-01
TW200630089A (en) 2006-09-01
WO2006052976A2 (en) 2006-05-18
CN101098696A (zh) 2008-01-02
WO2006052976A3 (en) 2006-08-17
CA2585446A1 (en) 2006-05-18
JP2008519584A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
BRPI0517976A (pt) métodos de tratamento
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
BRPI0606774A2 (pt) método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
ATE375796T1 (de) Verwendung von devazepide als schmerzmittel
UA3797U (uk) Спосіб лікування тяжких проникаючих поранень ока

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.